Skip to Content

Milrinone Pregnancy and Breastfeeding Warnings

Milrinone is also known as: Primacor, Primacor I.V.

Medically reviewed on March 13, 2018.

Milrinone Pregnancy Warnings

Milrinone has been assigned to pregnancy category C by the FDA. Animal studies failed to reveal evidence of teratogenicity at doses approximately 2.5 times the recommended human dosage. Studies have revealed increased resorption rates. There are no adequate or well-controlled studies during human pregnancy. Milrinone should only be given during pregnancy when benefit outweighs risk.

Placental transfer of milrinone was noted (baboon) when loading and continuous intravenous doses resulting in plasma concentrations considered therapeutic in human were administered. The maternal to fetal baboon serum ratio was approximately 4:1 during 3 hours of infusion.

See references

Milrinone Breastfeeding Warnings

There are no data on the excretion of milrinone into human milk.

See references

References for pregnancy information

  1. "Product Information. Primacor (milrinone)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  2. Atkinson BD, Fishburne JI, Hales KA, Levy GH, Rayburn WF "Placental transfer of milrinone in the nonhuman primate (baboon)." Am J Obstet Gynecol 174 (1996): 895-6

References for breastfeeding information

  1. "Product Information. Primacor (milrinone)." Sanofi Winthrop Pharmaceuticals, New York, NY.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide